利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

17 records (took 0.018 seconds)

    Diagnosis of sepsis and systemic inflammatory response syndrome
    3.
    发明授权
    Diagnosis of sepsis and systemic inflammatory response syndrome 有权

    公开(公告)号：US10712350B2

    公开(公告)日：2020-07-14

    申请号：US15373872

    申请日：2016-12-09

    Applicant: UNIVERSITÄTSKLINIKUM JENA

    Inventor： Michael Kiehntopf ,  Diana Schmerler ,  Thomas Deufel ,  Frank Brunkhorst

    IPC: G01N33/53 ,  G01N33/68 ,  C07K14/81 ,  G06F19/00 ,  G16H50/30 ,  C07K16/38

    Abstract: The present invention relates a method for the diagnosis, prediction or risk stratification for mortality and/or disease outcome of a subject that has or is suspected to have sepsis, comprising determining the presence and/or level of antitrypsin (ATT) or fragments thereof in a sample taken from said subject and/or determining the presence and/or level of transthyretin (TTR) or fragments thereof, wherein the presence and/or level of ATT and/or TTR or fragments thereof is correlated with an increased risk of mortality and, wherein said increased risk of mortality and/or poor disease outcome is given if the level of ATT is below a certain cut-off value and/or the level of fragments thereof is above a certain cut-off value and/or said increased risk of mortality and/or poor disease outcome is given if the level of TTR is below a certain cut-off value and/or the level of fragments thereof is below a certain cut-off value. The invention relates in general to the use of ATT and/or TTR or its fragments for the diagnosis of sepsis, and to nucleotides of SEQ ID NO. 2 to 14.

    DIAGNOSIS OF SEPSIS AND SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
    5.
    发明申请
    DIAGNOSIS OF SEPSIS AND SYSTEMIC INFLAMMATORY RESPONSE SYNDROME 审中-公开
    SEPSIS诊断和系统性炎症反应综合征

    公开(公告)号：US20140248631A1

    公开(公告)日：2014-09-04

    申请号：US13261860

    申请日：2012-11-14

    Applicant: UNIVERSITÄTSKLINIKUM JENA

    Inventor： Michael Kiehntopf ,  Diana Schmerler ,  Thomas Deufel ,  Frank Brunkhorst

    IPC: G01N33/53

    CPC classification number: G01N33/6893 ,  C07K14/8125 ,  C07K16/38 ,  C07K2317/34 ,  G01N33/5308 ,  G01N33/6848 ,  G01N2333/8125 ,  G01N2570/00 ,  G01N2800/26 ,  G01N2800/52 ,  G01N2800/56 ,  G16H50/30

    Abstract: The present invention relates a method for the diagnosis, prediction or risk stratification for mortality and/or disease outcome of a subject that has or is suspected to have sepsis, comprising determining the presence and/or level of antitrypsin (ATT) or fragments thereof in a sample taken from said subject and/or determining the presence and/or level of transthyretin (TTR) or fragments thereof, wherein the presence and/or level of ATT and/or TTR or fragments thereof is correlated with an increased risk of mortality and, wherein said increased risk of mortality and/or poor disease outcome is given if the level of ATT is below a certain cut-off value and/or the level of fragments thereof is above a certain cut-off value and/or said increased risk of mortality and/or poor disease outcome is given if the level of TTR is below a certain cut-off value and/or the level of fragments thereof is below a certain cut-off value. The invention relates in general to the use of ATT and/or TTR or its fragments for the diagnosis of sepsis, and to nucleotides of SEQ ID NO. 2 to 14.

    Abstract translation: 本发明涉及用于诊断，预测或风险分层的患者，其具有或怀疑具有败血症的受试者的死亡率和/或疾病结果，包括确定抗胰蛋白酶（ATT）或其片段的存在和/或水平 来自所述受试者的样品和/或确定转甲状腺素蛋白（TTR）或其片段的存在和/或水平，其中ATT和/或TTR或其片段的存在和/或水平与增加的死亡风险相关， 其中如果ATT的水平低于某一临界值和/或其片段的水平高于某一临界值和/或所述增加的风险，则给出所述增加的死亡风险和/或差的疾病结果的风险增加 如果TTR的水平低于某一截止值，和/或其片段的水平低于某一截止值，则给出死亡率和/或疾病不良结局。 本发明一般涉及ATT和/或TTR或其片段用于诊断败血症以及SEQ ID NO.1的核苷酸的用途。 2到14。

    MEDICAL IMPLANT BASED ON NANOCELLULOSE
    7.
    发明申请
    MEDICAL IMPLANT BASED ON NANOCELLULOSE 有权

    公开(公告)号：US20220071758A1

    公开(公告)日：2022-03-10

    申请号：US17526521

    申请日：2021-11-15

    Applicant: Universitätsklinikum Jena ,  KKF UG

    Inventor： Falk RAUCHFUSS ,  Utz SETTMACHER ,  Dieter KLEMM ,  Wolfgang FRIED ,  Thomas RICHTER ,  Katrin PETZOLD-WELCKE ,  Carola RUHE

    IPC: A61F2/04 ,  A61L31/14 ,  A61L31/00 ,  A61L31/10

    Abstract: Medical Implant (100), comprising a microbial cellulose tube (1), comprising a wall (2) having an inner surface (3) and an outer surface (4), wherein the wall comprises several layers (5, 6, 7) of microbial cellulose, wherein said layers are concentric or substantially concentric to a longitudinal axis (L) of the tube, a stent (9) which placed inside of the microbial cellulose tube (1), wherein an outer surface (10) of the stent contacts the inner surface (3) of the microbial cellulose tube (1), and method for producing such implant. The implant can be covered with newly created bile duct epithelium, thereby creating a new bile duct from body cells. The implant can be removed after completion of creation of the new bile duct. So, the implant as suitable as a temporary implant.
    The implant can be used for surgery, such as surgery of gall bladder, bile duct and/or liver, e.g. gall bladder removal, hepatobiliary malignancy surgery or liver transplantation. The implant can particularly be used for repairing or regeneration of bile duct. Further fields of use are the use as esophagus implant or urether implant.

    MEDICAL IMPLANT BASED ON NANOCELLULOSE
    10.
    发明申请
    MEDICAL IMPLANT BASED ON NANOCELLULOSE 审中-公开

    公开(公告)号：US20180221129A1

    公开(公告)日：2018-08-09

    申请号：US15749563

    申请日：2016-08-03

    Applicant: Universitätsklinikum Jena ,  KKF UG

    Inventor： Falk RAUCHFUSS ,  Utz SETTMACHER ,  Dieter KLEMM ,  Wolfgang FRIED ,  Thomas RICHTER ,  Katrin PETZOLD-WELCKE ,  Carola RUHE

    IPC: A61F2/04 ,  A61L31/14

    CPC classification number: A61F2/04 ,  A61F2002/041 ,  A61L31/005 ,  A61L31/10 ,  A61L31/146 ,  A61L2400/12 ,  A61L2420/08 ,  C08L1/02 ,  C08L1/00

    Abstract: Medical Implant (100), comprising—a microbial cellulose tube (1), comprising a wall (2) having an inner surface (3) and an outer surface (4), wherein the wall comprises several layers (5, 6, 7) of microbial cellulose, wherein said layers are concentric or substantially concentric to a longitudinal axis (L) of the tube,—a stent (9) which placed inside of the microbial cellulose tube (1), wherein an outer surface (10) of the stent contacts the inner surface (3) of the microbial cellulose tube (1), and method for producing such implant. The implant can be covered with newly created bile duct epithelium, thereby creating a new bile duct from body cells. The implant can be removed after completion of creation of the new bile duct. So, the implant as suitable as a temporary implant. The implant can be used for surgery, such as surgery of gall bladder, bile duct and/or liver, e.g. gall bladder removal, hepatobiliary malignancy surgery or liver transplantation. The implant can particularly be used for repairing or regeneration of bile duct. Further fields of use are the use as esophagus implant or urether implant.

Patent Agency Ranking